<DOC>
	<DOCNO>NCT01527552</DOCNO>
	<brief_summary>This trial conduct Africa . The aim trial investigate bioequivalence two formulation biphasic insulin aspart 50 healthy male subject .</brief_summary>
	<brief_title>Bioequivalence Two Formulations Biphasic Insulin Aspart 50 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Considered generally healthy upon completion medical history physical examination , judge investigator Body Mass Index ( BMI ) 1929 kg/m^2 ( inclusive ) Minimum body weight 65 kg Fasting blood glucose 3.86.0 mmol/L Glycohemoglobin ( HbA1c ) 6.4 % Nonsmokers Clinically significant abnormal hematology , biochemistry , urinalysis ECG ( electrocardiogram ) screening test , judge investigator A history illness , opinion Investigator and/or Sponsor , might confound result study pose additional risk administer investigational product subject History current addiction alcohol drug abuse determine investigator ( positive drug/alcohol abuse screen ) Hepatitis B C Subjects firstdegree relative diabetes mellitus Known suspect allergy trial product relate product Smoking past three month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>